

Takara Bio uses AWS DataSync to accelerate data transfer of their large genomic data results to Amazon S3

Challenge

- Media devices were used for data delivery of genome analysis and testing support. Collaboration on national projects and between pharmaceutical company users were limited as data transfer security and size were problematic for the existing infrastructure.
- Increased flexibility and availability was needed.

Solution

- AWS DataSync enabled secure, encrypted data transfer of large files into Amazon S3 with the speed Takara Bio needed.
- Takara Bio's S3 buckets were quickly and easily configured to meet project timelines.
- Amazon S3 optimized costs and enabled on-demand data delivery for global customers.
- AWS's global infrastructure offered scalability and reliability for sensitive data.

Benefits

- 66% reduction in operational load compared to traditional media device delivery.
- 2x data delivery speed gained using S3 cross account data copy, compared to media device delivery
- 3x faster upload speed from NAS Storage to S3 with DataSync
- Set tailored security level per each user

TAKARA BIO INC.

Company: Takara Bio Inc.
Industry: Science, Biotechnology
Country: Japan
Website: www.takara-bio.com

About Takara Bio Inc.

Takara Bio is a biotechnology business subsidiary of TAKARA SHUZO CO.,LTD. (currently TAKARA HOLDINGS INC.). Based on the corporate philosophy of "contributing to human health through the development of innovative biotechnologies such as gene therapy." Today, Takara Bio is a pharmaceutical research company that continuously creates new therapies by developing basic biopharmaceutical drug discovery technologies through its core businesses of "Research Reagents & Scientific Instruments" and "CDMO".



The combination of fast and secure data transfer by AWS DataSync and the large storage capacity of Amazon S3 allowed us to smoothly deliver genome data, which is becoming increasingly large. We will continue to build an analysis platform using AWS for personalized medicine using whole genome sequencing, which is expected to increase in the future.

Satoshi Kira, Product Development Center Lead, Takara Bio Inc.

